Tolerability of PLD/oxaliplatin regimen in recurrent ovarian cancer patients with previous fragility to carboplatin/paclitaxel treatment

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 34, Issue 3, 2011, Pages 305-308

  Palma, Maurizia Dalla ^a   Lombardi, Giuseppe ^a   Donach, Martin E ^b   Borgato, Lucia ^a   Zustovich, Fable ^a   Furini, Lara ^a   Nicoletto, Maria O ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

carboplatin; myelotoxicity; ovarian cancer; oxaliplatin; paclitaxel; pegylated liposomal doxorubicin

Indexed keywords

CARBOPLATIN; DOXORUBICIN; HORMONE; OXALIPLATIN; PACLITAXEL;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BONE MARROW DEPRESSION; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVARY CANCER; OVERALL SURVIVAL; RECURRENT CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; DISEASE PROGRESSION; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; PACLITAXEL; POLYETHYLENE GLYCOLS; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 79958292487     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e3181e1cb22     Document Type: Article

References (28)

1. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18:3084-3092.
2. Du Bois A, Neijt JP, Thigpen JT. First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer-a new standard of care? Ann Oncol. 1999;10(suppl 1):35-41.
3. Ozols RF. Chemotherapy for ovarian cancer. Semin Oncol. 1999;26:34-40. (Pubitemid 30013261)
4. Du Bois A, Lueck HJ, Meier W, et al. Cisplatin/paclitaxel vs. carboplatin/ paclitaxel in ovarian cancer: update of an Arbeisgemeinschaft Gynaekologische Onkologie (AGO) Study Group trial. Proc Am Soc Clin Oncol. 1999;18: 356a.
5. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194-3200. (Pubitemid 46606249)
6. Bookman MA, Greer BE, Ozols RF. Optimal therapy of advanced ovarian cancer: carboplatin and paclitaxel versus cisplatin and paclitaxel (GOG158) and an update on GOG0182-ICON5. Int J Gynecol Cancer. 2003;13(suppl 2):149-155. (Pubitemid 38228757)
7. Du Bois A, Quinn M, Thigpen T, et al. 2004 consensus statements on the management of ovarian cancer: final document of the 3rd International Gynecologic Cancer Intergroup Ovarian Cancer Consensus Conference (GCIG OCCC 2004). Ann Oncol. 2005;16(suppl 8):viii7-viii12. (Pubitemid 41631227)
8. Alberts DS, Green S, Hannigan EV, et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer. J Clin Oncol. 1992;10:706-717.
9. Markman M, Hoskins W. Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population. J Clin Oncol. 1992;10:513-514.
10. Vasey PA, Jayson GC, Gordon A, et al. Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004;96:1682-1691. (Pubitemid 39585637)
11. Peintinger F, Georgoulopoulos A, Ralph G, et al. Retrospective comparison of chemotherapy-induced myelotoxicity in patients with ovarian cancer under and over 60 years of age. J Chemother. 2006;18:656-661. (Pubitemid 46045398)
12. Markman J, Zanotti K, Webster K, et al. Experience with the management of neutropenia in gynecologic cancer patients receiving carboplatin-based chemotherapy. Gynecol Oncol. 2004;92:592-595. (Pubitemid 38183149)
13. Jodrell DI, Egorin MJ, Canetta RM, et al. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10:520-528.
14. Jakobsen A, Bertelsen K, Andersen JE, et al. Dose-effect study of carboplatin in ovarian cancer: a Danish Ovarian Cancer Group study. J Clin Oncol. 1997;15:193-198. (Pubitemid 27020573)
15. Nicoletto MO, Falci C, Pianalto D, et al. Phase II study of pegylated liposomal doxorubicin and oxaliplatin in relapsed advanced ovarian cancer. Gynecol Oncol. 2006;100:318-323. (Pubitemid 43075263)
16. Recchia F, Saggio G, Amiconi G, et al. A multicenter phase II study of pegylated liposomal doxorubicin and oxaliplatin in recurrent ovarian cancer. Gynecol Oncol. 2007;106:164-169. (Pubitemid 46898588)
17. Fink D, Zheng H, Nebel S, et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Res. 1997;57:1841-1845. (Pubitemid 27209707)
18. Rixe O, Ortuzar W, Alvarez M, et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol. 1996;52:1855-1865. (Pubitemid 26419675)
19. Mathe G, Kidani Y, Segiguchi M, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum and carboplatinum. Biomed Pharmacother. 1989;43:237-250. (Pubitemid 19153975)
20. Chollet P, Bensmaine MA, Brienza S, et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol. 1996;7:1065-1070. (Pubitemid 27050831)
21. Soulie P, Bensmaine A, Garrino C, et al. Oxaliplatin/cisplatin (L-OHP/ CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer. 1997;33:1400-1406. (Pubitemid 27404897)
22. Hochster H, Chen TT, Lu JM, et al. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecol Oncol. 2008;108:500-504.
23. Extra JM, Espie M, Calvo F, et al. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol. 1990;25:299-303. (Pubitemid 20014976)
24. Culy CR, Clemett D, Wiseman LR. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs. 2000;60:895-924.
25. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter- randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol. 2000;18: 136-147. (Pubitemid 30036347)
26. Kollmannsberger C, Mayer F, Harstrick A, et al. Reduction of skin toxicity of pegylated liposomal doxorubicin (PLD) by concomitant administration of dexamethasone and pyridoxine in patients (pts) with anthracyclin-sensitive malignancies-a phase I/II trial. 25th Congress of the European Society of Medical Oncology. Ann Oncol. 2000;11(suppl 4):136. Abstract 623P.
27. von Moos R, Thuerlimann BJ, Aapro M, et al. Pegylated liposomal doxorubicin- associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer. 2008;44:781-790.
28. Nicoletto MO, Bertorelle R, Borgato L, et al. Family history of cancer rather than p53 status predicts efficacy of pegylated liposomal doxorubicin and oxaliplatin in relapsed ovarian cancer. Int J Gynecol Cancer. 2009;19:1022-1029.